GSK in­vests $270M in­to vac­cine man­u­fac­tur­ing in Bel­gium

GSK is in­vest­ing about $270 mil­lion (€250 mil­lion) to build out and ex­pand its vac­cine man­u­fac­tur­ing fa­cil­i­ties in Wavre, Bel­gium.

The plant is ex­pect­ed to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER